IceCure Medical Ltd ICCM

Company Overview

IceCure Medical Ltd. is an Israel-based medical device company focused on minimally invasive cryoablation technology for the treatment of tumors and other tissue-related conditions. The company operates within the medical technology and interventional oncology sectors, with its primary commercial platform centered on liquid nitrogen–based cryoablation systems designed to destroy tumors through controlled freezing. IceCure’s flagship technology platform, ProSense®, is used in procedures involving breast, kidney, lung, liver, and bone tumors, among other indications. The company generates revenue primarily through the sale of cryoablation systems, disposable probes, and related procedural products and services.

IceCure’s principal customer base includes hospitals, surgical centers, oncology clinics, and interventional radiology practitioners across multiple international markets. The company has positioned itself around minimally invasive alternatives to traditional surgical oncology procedures, particularly in breast tumor treatment for patients seeking reduced recovery times and less invasive intervention. Founded in 2006 and headquartered in Caesarea, Israel, IceCure expanded through clinical development programs, regulatory approvals in multiple jurisdictions, and partnerships with healthcare providers and distributors. Public filings and company disclosures indicate that the company’s strategic focus has increasingly emphasized breast cancer applications and broader adoption of office-based cryoablation procedures.

Business Operations

IceCure conducts operations primarily through the commercialization and clinical advancement of its ProSense® cryoablation platform and related disposable products. Revenue is derived from capital equipment sales, recurring sales of single-use cryoprobes, and service-related activities. The company operates internationally, with commercial activity reported across North America, Europe, Asia-Pacific, and selected markets in Latin America. IceCure’s technology portfolio includes proprietary cryogenic systems that utilize liquid nitrogen for precise tissue ablation, allowing minimally invasive image-guided procedures.

The company maintains direct operations as well as distributor-based commercial relationships in several regions. IceCure has pursued collaborations with hospitals, physicians, and clinical research institutions to support adoption and regulatory expansion. Public disclosures identify ongoing clinical studies and post-market evaluation programs related to breast cancer treatment and other oncological applications. The company also relies on intellectual property protections covering cryoablation technologies, system design, and procedural methodologies. Data regarding certain partnership economics and specific distribution arrangements is inconclusive based on available public sources.

Strategic Position & Investments

IceCure’s strategic direction has focused on expanding clinical validation and regulatory acceptance of minimally invasive cryoablation as an alternative to conventional surgery, particularly for early-stage breast cancer. A major component of the company’s strategy has involved the advancement of the ICE3 clinical trial program evaluating cryoablation outcomes in low-risk breast cancer patients. The company has also pursued regulatory submissions and reimbursement-related initiatives intended to increase physician adoption and healthcare system integration.

In recent years, IceCure has invested in product development, expanded manufacturing capabilities, and international commercialization efforts. The company has emphasized broader utilization of office-based and outpatient oncology procedures, aligning with healthcare trends favoring minimally invasive treatment models. IceCure’s portfolio remains concentrated around cryoablation technology rather than diversified healthcare holdings, and publicly available records do not indicate large-scale acquisition activity comparable to major medical device conglomerates. The company’s strategic positioning is tied closely to emerging interventional oncology practices, imaging-guided therapies, and lower-cost alternatives to traditional surgical interventions.

Geographic Footprint

IceCure is headquartered in Caesarea, Israel, and maintains a global commercial presence through direct sales activity and distributor relationships. The company’s products have received regulatory clearances in multiple jurisdictions, including the United States, the European Union, and parts of Asia-Pacific. The company has highlighted commercial and clinical activities in Israel, North America, Europe, China, and additional international markets through public filings and investor communications.

The company’s operational influence is strongest in developed healthcare markets where minimally invasive oncology procedures and interventional radiology infrastructure are established. IceCure has also sought expansion opportunities in emerging international healthcare systems through partnerships and regional distribution networks. Publicly available information indicates ongoing efforts to broaden physician adoption globally, although market penetration levels vary substantially by region.

Leadership & Governance

IceCure’s leadership team combines experience in medical devices, oncology technologies, commercialization, and public company management. Strategic leadership has emphasized clinical validation, regulatory expansion, and physician adoption of minimally invasive cryoablation technologies. Governance oversight is conducted through the company’s board of directors and executive leadership structure as disclosed in public filings and corporate reports.

Key executives include:

• Eyal Shamir – Chief Executive Officer
• Ran Schorer – Chief Financial Officer
• Dr. Mark Klein – Chairman of the Board
• Talia Rachmilewitz, Ph.D. – Vice President of Business Development
• Yaron Sasi – Vice President of Research and Development

Public disclosures indicate that management’s strategic vision centers on expanding the use of cryoablation in breast cancer and other oncology applications while pursuing regulatory milestones, clinical evidence generation, and broader commercial adoption of the ProSense® platform.